Tango Therapeutics (TNGX) News Today $1.94 -0.11 (-5.37%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.94 0.00 (0.00%) As of 05/28/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Woodline Partners LP purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 394,397 shares of the company's stock, valued at approximately $1,219,000. Woodline Partners LP owned 0.May 28 at 4:30 AM | marketbeat.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27 at 10:32 PM | finance.yahoo.comTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceMay 27 at 7:00 AM | globenewswire.comTango Therapeutics starts trial for brain cancer drugMay 23, 2025 | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21, 2025 | globenewswire.com517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 517,426 shares of the company's stock, valued at approxMay 19, 2025 | marketbeat.comQ2 EPS Estimate for Tango Therapeutics Increased by AnalystTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for Tango Therapeutics in a report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings pMay 17, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)Dimensional Fund Advisors LP lifted its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 83.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 662,776 shares of the company's stock after puMay 17, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 16, 2025 | finance.yahoo.comOrbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Orbimed Advisors LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 550,000 shares of the company's stock, valued atMay 15, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPSTango Therapeutics (NASDAQ:TNGX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.May 14, 2025 | marketbeat.comTango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline DevelopmentsMay 14, 2025 | nasdaq.comTango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finanznachrichten.deTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finance.yahoo.comTango Therapeutics Extends Cash Runway Amid Clinical ProgressMay 13, 2025 | tipranks.comTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 12, 2025 | globenewswire.com4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLCFarallon Capital Management LLC bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,000,000 shares of the company's stock, valued at approximatMay 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Balyasny Asset Management L.P. raised its position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,279,196 sharesMay 11, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by AnalystsTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price objeMay 11, 2025 | marketbeat.comTango Therapeutics (TNGX) to Release Quarterly Earnings on MondayTango Therapeutics (NASDAQ:TNGX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-tango-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comBoxer Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)Boxer Capital Management LLC purchased a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,380,999 shares of the company's stock,May 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)Susquehanna Fundamental Investments LLC acquired a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 347,271 shares of the compaMay 4, 2025 | marketbeat.comTCG Crossover Management LLC Invests $33.17 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)TCG Crossover Management LLC bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,736,000 shares of tMay 1, 2025 | marketbeat.comTango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 1, 2025 | globenewswire.comNantahala Capital Management LLC Invests $8.67 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)Nantahala Capital Management LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,804,410 shares of the company's stock, valued at approximately $8,666,000. NaApril 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Trims Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)T. Rowe Price Investment Management Inc. cut its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,345,551 shares of the company's stock after selling 1,677,595 sharApril 30, 2025 | marketbeat.comBlue Owl Capital Holdings LP Acquires New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)Blue Owl Capital Holdings LP bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,732,152 shares of the companyApril 26, 2025 | marketbeat.comTrv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)Trv Gp Vi LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 194,174 shares of the company's sApril 22, 2025 | marketbeat.comGilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)Gilead Sciences Inc. bought a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,854,443 shares of the company's stock, valued at approximatelyApril 20, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for TNGXTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Tango Therapeutics in a research report issued on Monday, April 14th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.35) per share for theApril 18, 2025 | marketbeat.comQ1 Earnings Forecast for TNGX Issued By HC WainwrightTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, April 14th. HC Wainwright analyst R. Burns forecasts that the companyApril 17, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from AnalystsTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price target amonApril 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday.April 16, 2025 | marketbeat.comBarbara Weber, M.D., Elected to ITM Supervisory BoardApril 9, 2025 | markets.businessinsider.comSchroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)Schroder Investment Management Group bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 655,158 shares of the company's stock, valued at aApril 8, 2025 | marketbeat.comShort Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 9,110,000 shares, an increase of 29.4% from the February 28th total of 7,040,000 shares. Approximately 15.4% of the shares of the company are sold short. Based on an average daily volume of 873,500 shares, the days-to-cover ratio is presently 10.4 days.April 1, 2025 | marketbeat.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comBarclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)March 24, 2025 | markets.businessinsider.comTango Therapeutics, Inc. (NASDAQ:TNGX) Sees Large Growth in Short InterestTango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 7,040,000 shares, a growth of 18.5% from the February 13th total of 5,940,000 shares. Approximately 11.9% of the shares of the stock are sold short. Based on an average daily volume of 967,300 shares, the short-interest ratio is currently 7.3 days.March 19, 2025 | marketbeat.comCantor Fitzgerald Has Weak Estimate for TNGX FY2025 EarningsTango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst E. SchmidMarch 12, 2025 | marketbeat.comTango Therapeutics (TNGX) Expected to Announce Earnings on MondayTango Therapeutics (NASDAQ:TNGX) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comTango Therapeutics (TNGX) Receives a Buy from BarclaysMarch 1, 2025 | markets.businessinsider.comTango Therapeutics (NASDAQ:TNGX) Issues Earnings ResultsTango Therapeutics (NASDAQ:TNGX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.February 28, 2025 | marketbeat.comTango Therapeutics Advances Cancer Treatment PipelineFebruary 28, 2025 | tipranks.comTango Therapeutics sees cash runway into 3Q26February 27, 2025 | markets.businessinsider.comTango Therapeutics reports Q4 EPS (35c), consensus (34c)February 27, 2025 | markets.businessinsider.comTango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business HighlightsFebruary 27, 2025 | globenewswire.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The averagFebruary 23, 2025 | marketbeat.comTango Therapeutics to Present at Three Upcoming Investment Bank ConferencesFebruary 20, 2025 | markets.businessinsider.comShort Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 22.5%Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 5,440,000 shares, a decrease of 22.5% from the January 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 11.0% of the shares of the company are sold short.February 15, 2025 | marketbeat.com Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Media Mentions By Week TNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNGX News Sentiment▼0.360.87▲Average Medical News Sentiment TNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNGX Articles This Week▼53▲TNGX Articles Average Week Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PAHC News Today ARDX News Today COLL News Today NTLA News Today RCUS News Today AVDL News Today SYRE News Today PHVS News Today CRMD News Today CVAC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNGX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
